Elsevier

Experimental Neurology

Volume 167, Issue 1, January 2001, Pages 196-204
Experimental Neurology

Regular Article
The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity

https://doi.org/10.1006/exnr.2000.7542Get rights and content

Abstract

Excitotoxic lesions of the striatum are mediated by the combined activity of N-methyl-d-aspartate (NMDA) receptors and metabotropic glutamate receptors (mGluRs). Intrastriatal injection of the NMDA receptor agonists NMDA or quinolinic acid creates large lesions, but in rats that have been decorticated to remove endogenous glutamatergic input, NMDA and quinolinic acid are no longer toxic. We report that NMDA toxicity can be restored in decorticated animals by coinjection of the group I mGluR agonists t-ACPD, t-ADA, or CHPG. In addition, injections of two group I mGluR antagonists, AIDA and (S)-4C3HPG, can protect against striatal lesions produced by quinolinic acid or NMDA injections in normal rats by blocking activation of group I mGluRs. The group II mGluR agonist APDC fails to protect against quinolinic acid or NMDA toxicity in intact animals or to restore NMDA toxicity in decorticated animals, suggesting that the role of group II receptors in this excitotoxic model is minimal. These observations confirm the important role of group I mGluRs in excitotoxicity and identify these receptors as promising targets for therapeutic intervention in neurodegenerative disease processes.

References (59)

  • M DiFiglia

    Excitotoxic injury of the neostriatum: A model for Huntington's disease

    TINS

    (1990)
  • A.J. Doherty et al.

    (RS)-2-Chloro-5-hydroxyphenylglycine (CHPG) activates mGlu(5), but not mGlu(1), receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus

    Neuropharmacology

    (1997)
  • S.J. East et al.

    Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes

    Eur. J. Pharmacol.

    (1995)
  • C.R Gerfen

    The neostriatal mosaic: Multiple levels of compartmental organization

    Trends Neurosci.

    (1992)
  • A.M Graybiel

    Neurotransmitters and neuromodulators in the basal ganglia

    Trends Neurosci.

    (1990)
  • J. Greenamyre et al.

    Exitatory amino acids and Alzheimer's disease

    Neurobiol. Aging

    (1989)
  • Y. Kawaguchi et al.

    Striatal interneurones: Chemical, physiological and morphological characterization

    Trends Neurosci.

    (1995)
  • J.A. Kerner et al.

    Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus

    Brain Res. Mol. Brain Res.

    (1997)
  • N.W. Kowall et al.

    Patterns of cell loss in Huntington's disease

    TINS

    (1987)
  • S. Kwak et al.

    Neurotoxicity of (2S,1′R,2′R,3′R)-2-(2,3-dicarboxycycloproply)glycine, a potent agonist for class II metabotropic glutamate receptors, in the rat

    Neuroscience

    (1996)
  • B. Meldrum et al.

    Excitatory amino acid neurotoxicity and neurodegenerative diseases

    Trends Pharmacol. Sci.

    (1990)
  • D.T. Monaghan et al.

    Quinolinate differentiates between forebrain and cerebellar NMDA receptors

    Eur. J. Pharmacol.

    (1991)
  • A. Neki et al.

    Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: An immunohistochemical study with a monoclonal antibody

    Neurosci. Lett.

    (1996)
  • F. Nicoletti et al.

    Group-I metabotropic glutamate receptors: Hypotheses to explain their dual role in neurotoxicity and neuroprotection

    Neuropharmacology

    (1999)
  • L.R. Orlando et al.

    Metabotropic receptors in excitotoxicity: (S)-4-Carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions

    Neurosci. Lett.

    (1995)
  • D.E. Pellegrini-Giampietro et al.

    Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms

    Neuropharmacology

    (1999)
  • R.S. Petralia et al.

    The metabotropic glutamate receptors, mGluR2 and mGluR3 show unique postsynaptic, presynaptic and glial localizations

    Neuroscience

    (1996)
  • J.P. Pin et al.

    Neurotransmitter receptors. I. The metabotropic glutamate receptors: Structure and functions

    Neuropharmacology

    (1995)
  • D.D. Schoepp et al.

    Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate

    Neuropharmacology

    (1995)
  • Cited by (63)

    • Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences

      2018, Progress in Neurobiology
      Citation Excerpt :

      Among the BG, the globus pallidus has the lowest NMDAR density (Ozawa et al., 1998), but suffers from glutamate-induced toxicity because of the high density of postsynaptic metabotropic mGluR1 receptor (Martin et al., 1992). Group I mGluRs have a predominant role in excitotoxicity compared to group II mGluRs (Orlando et al., 2001), and the high expression of mGluR1 among MSNs participates in MSNs peculiar vulnerability to excitotoxic insults (Testa et al., 1998). Indeed, mGluR1 promote calcium inward currents even in absence of NMDAR stimulus, promoting a backdoor pathway to reach excitotoxicity which is independent from the activation of the synapse (Bernal et al., 2000; Giribaldi et al., 2013).

    • Metabotropic glutamate receptor 1 (mGluR1): Antibody specificity and receptor expression in cultured primary neurons

      2012, Journal of Neuroscience Methods
      Citation Excerpt :

      These receptors are predominately localized postsynaptically, where they couple to phosphoinositide hydrolysis to impact plasticity, learning and memory, excitotoxicity, and a number of other synaptic processes. We have studied the group I mGluRs for a number of years, in both in vivo and in vitro systems (Orlando et al., 1995, 2001, 2002, 2009). It was through our recent efforts generating and characterizing novel phosphospecific mGluR antibodies (Orlando et al., 2009) that we discovered that some previously tried-and-true mGluR1 antibodies were no longer reliable.

    View all citing articles on Scopus
    View full text